Skip to main content
Retour
Watch Compare

Nuo Therapeutics, Inc.

Qualité des données : 83%
AURX
OTC Manufacturing Measuring & Analyzing Instruments
1,70 €
0,00 € (0,00%)
Cap. Boursière: 82,09 M
Prix
1,70 €
Cap. Boursière
82,09 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—

Quick Summary

Points Clés

Negative free cash flow of -1,14 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROIC-385,42%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio1,16
Interest CoverageN/A

Valorisation

PE (TTM)
-32,68
En dessous de la moyenne du secteur (-1,47)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -32,7 -1,5
P/B — 1,6
ROE % — -53,3
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Objectif de Cours des Analystes

1 analyste
Buy
Actuel
1,70 €
+76.5%
Objectif
3,00 €
3,00 €
3,00 €
3,00 €
Prévisions
P/E Prévisionnel -170,00
BPA Prévisionnel -0,01 €
CA Est. 9,46 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2027 -0,01 €
-0,01 € – -0,01 €
 9,46 M 1
FY2026 -0,04 €
-0,04 € – -0,04 €
 5,75 M 1

Surprises de Résultats

Derniers 2 trimestres
Trimestre BPA Est. BPA Réel Surprise
Q42025 -0,01 € -0,01 € 0,0%
Q32025 N/A -0,01 € —

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -2,51 M
ROE N/A ROA -152,85%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -1,14 M
ROIC -385,42% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1,16
Interest Coverage N/A Asset Turnover N/A
Working Capital 206 167 Tangible Book Value -419 606
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -32,68 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -1,39%
Market Cap 82,09 M Enterprise Value 81,58 M
Per Share
EPS (Diluted TTM) N/A Revenue / Share N/A
FCF / Share -0,02 OCF / Share -0,02
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 45,37%
SBC-Adj. FCF -1,22 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -2,51 M -2,32 M -3,17 M -3,17 M -90 670,0
EPS (Diluted) — — — — -0,03
Gross Profit 2,22 M 1,06 M 482 433,0 93 036,0 0,0
Operating Income -2,52 M -2,46 M -3,17 M -3,32 M -90 670,0
EBITDA — — — — —
R&D Expenses — — — — 0,0
SG&A Expenses 4,73 M 3,52 M 3,65 M 3,41 M —
D&A — — — — 0,0
Interest Expense — — — — 0,0
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,85 M 1,19 M 1,88 M 3,05 M 1,47 M
Total Liabilities 2,80 M 675 796,0 838 732,0 856 022,0 673 079,0
Shareholders' Equity -956 559,0 513 712,0 1,04 M 2,19 M 792 839,0
Total Debt — — — — 0,0
Cash & Equivalents 548 946,0 283 714,0 928 681,0 2,05 M 1,41 M
Current Assets 1,38 M 841 546,0 1,56 M 2,63 M 1,47 M
Current Liabilities 1,31 M 578 451,0 674 527,0 600 431,0 673 079,0